{"ticker": {"uuid": "b28eccc3-8097-4c66-ad0e-6aa5c5eda64e", "symbol": "CGEN", "name": "Compugen", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes Compugen Ltd's (CGEN) valuation, noting its current valuation score is 7.48, placing it 228th out of 389 in the Biotechnology & Medical Research industry. CGEN's P/E ratio stands at 5.36, significantly below its recent high and above its recent low. However,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T05:09:59", "published_display": "19 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Compugen Ltd (CGEN), detailing its price momentum score of 6.72 and its ranking in the Biotechnology & Medical Research industry. It highlights the stock's current trading range between support at $1.67 and resistance at $2.64, suitab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/technical", "source_name": "TradingKey", "published_at": "2026-06-18T17:40:40", "published_display": "18 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen presents ovarian cancer trial poster at ESMO meeting", "summary": "Compugen Ltd. presented a trial-in-progress poster for its MAIA-ovarian adaptive platform trial of COM701 at the ESMO Gynaecological Cancers Congress. The company is evaluating COM701 as a maintenance treatment for relapsed platinum-sensitive ovarian cancer, with initial data exp", "url": "https://m.uk.investing.com/news/stock-market-news/compugen-presents-ovarian-cancer-trial-poster-at-esmo-meeting-93CH-4735079?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T17:09:04", "published_display": "18 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/compugen-presents-trial-progress-poster-110000732.html", "source_name": "PR Newswire", "published_at": "2026-06-18T11:00:00+00:00", "published_display": "18 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen spotlights COM701 ovarian trial at ESMO congress", "summary": "Compugen (Nasdaq: CGEN) presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress 2026 for its MAIA-ovarian adaptive platform trial of COM701. COM701 is a potential first-in-class anti-PVRIG antibody being evaluated as a maintenance treatment for relapsed p", "url": "https://www.stocktitan.net/news/CGEN/compugen-presents-a-trial-in-progress-poster-on-the-maia-ovarian-1ujs4cnexnts.html", "source_name": "Stock Titan", "published_at": "2026-06-18T10:39:17", "published_display": "18 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Institutional Confidence", "summary": "Compugen Ltd (CGEN) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding stands at 14.54%, a 16.20% decrease quarter-over-quarter. James Simons is the largest instituti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:17", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Compugen Ltd (CGEN), noting its financial score of 6.25 and ranking in the Biotechnology & Medical Research industry. It highlights the company's robust financial status despite low operating efficiency, with recent quarterly revenue ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:25", "published_display": "18 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions", "summary": "Compugen (CGEN) is experiencing mixed analyst sentiment, with one firm significantly lowering its price target from US$13 to US$5, while another maintains a fair value estimate at US$4.6. Despite some bullish takes and continued \"Outperform\" ratings, more cautious voices cite tig", "url": "https://uk.finance.yahoo.com/news/compugen-cgen-stock-faces-mixed-043936924.html", "source_name": "Market source", "published_at": "2026-06-18T04:39:17", "published_display": "18 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBJU0R2M0VwQWdybFdtWEtJdTV2NFVnRWoyU0FCYUNfbHF1d19lblZBZUZ3ZFhXTF91SVpzLXdOLWttZ3JUVWV6clZSUGtDSGxaM3dwQ29sYmN3ZUs4bS1tUnMxYkprMGpZcDk1a0Vn?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T20:57:48+00:00", "published_display": "17 Jun 2026 20:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Compugen Ltd (CGEN) has an earnings forecast score of 9.20, ranking 8th in its industry, with analysts assigning a Strong Buy rating and an average price target of $4.00. The company's EPS for the previous quarter was $0.60, significantly exceeding market expectations, and the ne", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:17", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE4tdUp5dnlpZTVmUjRLWFk1aWRoNE5vWmJQQ0ZaTS1RUEpzLU9PNFpNeEhycWVXNEdSd25wcXRYT0g4NUd0N0QzTC1GQUtxM2gtdXRmcGpRZFhoREZUSUg1aVIwV1R0TUtnQnJkX0liVGI3ZHd6Rmlj?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T20:25:31+00:00", "published_display": "17 Jun 2026 20:25", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Compugen Ltd (CGEN) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also presents current stock price inform", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:17", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026", "summary": "Compugen Ltd. announced it will present a poster on its MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The poster will detail the adaptive platform clinical trial evaluating the safety and efficacy of COM701 maintenance treatment in relapse", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compugen-present-phase-1-maia-110000380.html", "source_name": "Market source", "published_at": "2026-06-12T02:10:11", "published_display": "12 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) to Present MAIA-Ovarian Trial Progress at Eu", "summary": "Compugen Ltd (CGEN) announced it will present progress on its MAIA-ovarian trial at the ESMO Gynecological Cancers Congress in June 2026. GuruFocus rates CGEN as 61.0% undervalued with a GF Value of $5.12, but flags it as a \"Possible Value Trap\" due to mixed profitability and gro", "url": "https://www.gurufocus.com/news/8912266/compugen-ltd-cgen-to-present-maiaovarian-trial-progress-at-european-oncology-congress?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-11T18:40:26", "published_display": "11 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen to present ovarian cancer trial poster at ESMO", "summary": "Compugen Ltd. announced it will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study at the ESMO Gynaecological Cancers Congress 2026. The study evaluates COM701 as a maintenance treatment for relapsed platinum-sensitive ovarian cancer. This news follows Compugen'", "url": "https://m.uk.investing.com/news/stock-market-news/compugen-to-present-ovarian-cancer-trial-poster-at-esmo-93CH-4723510?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-11T15:09:28", "published_display": "11 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI-driven cancer firm to present ovarian trial at ESMO 2026", "summary": "Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The presentation will cover COM701 maintenance treatment in relapsed plati", "url": "https://www.stocktitan.net/news/CGEN/compugen-to-present-phase-1-maia-ovarian-trial-in-progress-poster-at-59j5ab82cr00.html", "source_name": "Stock Titan", "published_at": "2026-06-11T10:39:43", "published_display": "11 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development", "summary": "Compugen Ltd. (Nasdaq: CGEN) announced its participation in Jones Trading's \"Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ML-based Drug Development\" on Monday, June 15, 2026. The company, a clinical-stage cancer immunotherapy firm leveraging it", "url": "https://www.tradingview.com/news/prnewswire:1bdb72de337c1:0-compugen-to-participate-in-jones-trading-fireside-chat-series-with-leaders-in-ai-ml-based-drug-development/", "source_name": "TradingView", "published_at": "2026-06-08T11:10:35", "published_display": "08 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] COMPUGEN LTD SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOdkFZVEpYaWhQVDBYc2lJNWlnQVhuOXRZem9OUDRuU1d2MVdrcVY4NzJ2T1lOVUljZVluZWdVWVc2a1lHMVJyanpRWFRKLTVRTnJya1h6dWdzcnJVdFR6VUwyUC1uazVOTDlUOVJHNnNSUjBZSWQ2YUJnLVM3Njlod3Fhd0dYRl9FR3FoS0RaVXc0YkRrSHg4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Compugen stock rating on ASCO data", "summary": "H.C. Wainwright has reiterated its Buy rating and $4.00 price target for Compugen shares (NASDAQ:CGEN) following positive updates on rilvegostomig presented at ASCO, a drug developed in partnership with AstraZeneca. Despite strong clinical data that validates the TIGIT mechanism ", "url": "https://m.uk.investing.com/news/stock-market-news/hc-wainwright-reiterates-compugen-stock-rating-on-asco-data-93CH-4713691?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-04T13:09:22", "published_display": "04 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Compugen stock rating on ASCO data By Investing.com", "summary": "H.C. Wainwright reiterated a Buy rating and a $4.00 price target for Compugen (NASDAQ: CGEN) following updates on rilvegostomig data presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting. AstraZeneca, Compugen's partner, provided positive updates on th", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-compugen-stock-rating-on-asco-data-93CH-4675770", "source_name": "Investing.com Canada", "published_at": "2026-06-04T11:42:17", "published_display": "04 Jun 2026 11:42", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOS1lOWVhKRGJBSERJeTktbmpUbWMzNFc4NlBhN0g5ajFjdjhSNlRsekVuczBDQXRBVlJ6dkdwUFZUWWU1NWswWTFpSTh3cHNod3pYV2FCNjN5VFBtNGhXSkRqenlZTmNSOEcyc2dtTFFOYTZFbzNBdVhWSURvd3hmYWN3N3FQM1VacTFEZl83UldiVFNMSUl2T2szWXRFRFBweUN5dEpn?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Q1 2026 Earnings Call: Complete Transcript", "summary": "Compugen discussed its Q1 2026 financial results, highlighting a strong cash runway extending into 2029 following a $65 million transaction with AstraZeneca. The company is actively enrolling patients for its COM701 clinical program for ovarian cancer, with interim data expected ", "url": "https://www.sahmcapital.com/news/content/compugen-q1-2026-earnings-call-complete-transcript-2026-06-01", "source_name": "Sahm", "published_at": "2026-06-01T11:09:22", "published_display": "01 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Compugen to Report Financial Results Pre-market on May 18", "summary": "Compugen Ltd. (NASDAQ: CGEN) is scheduled to release its financial results for the first quarter of 2026 before the market opens on Saturday, May 18, 2026. The company will also host a conference call and live webcast to discuss the results and provide a corporate update. Investo", "url": "https://www.moomoo.com/news/post/69868944/earnings-preview-compugen-to-report-financial-results-pre-market-on", "source_name": "Moomoo", "published_at": "2026-05-27T23:09:43", "published_display": "27 May 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges", "summary": "Compugen Ltd (CGEN) reported Q1 2026 results highlighting strategic advances in its COM701 clinical program for ovarian cancer and a solid cash runway into 2029. Despite a slight revenue dip and increased R&D expenses leading to a higher net loss, the company emphasized promising", "url": "https://ca.investing.com/news/company-news/compugen-ltd-cgen-q1-2026-earnings-call-highlights-strategic-advances-amid-financial-challenges-4658310", "source_name": "Investing.com Canada", "published_at": "2026-05-26T03:10:36", "published_display": "26 May 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5", "summary": "Leerink Partners has reiterated its Buy rating for Compugen (CGEN.US) but has revised its price target downward to $5. This adjustment reflects an updated outlook from the analytical firm while still signaling confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/70380757/leerink-partners-maintains-compugen-cgenus-with-buy-rating-cuts-target", "source_name": "Moomoo", "published_at": "2026-05-22T18:09:39", "published_display": "22 May 2026 18:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEN Maintains Outperform Rating -- Price Target Lowered to $5.0", "summary": "Leerink Partners has maintained an \"Outperform\" rating for Compugen (CGEN) but significantly lowered its price target from $13.00 to $5.00, reflecting a reassessment of its market position despite ongoing clinical-stage programs. Although the stock is considered undervalued by Gu", "url": "https://www.gurufocus.com/news/8875120/cgen-maintains-outperform-rating-price-target-lowered-to-500-by-leerink-partners", "source_name": "GuruFocus", "published_at": "2026-05-21T16:39:42", "published_display": "21 May 2026 16:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Returns To Loss In Q1 2026 And Tests Bullish Profitability Narrative", "summary": "Compugen (CGEN) reported a loss of US$7.7 million in Q1 2026 with revenue of US$2.2 million, challenging its recent profitability narrative. The majority of its trailing twelve-month revenue was driven by a single large payment in Q4 2025, raising questions about revenue stabilit", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgen/compugen/news/compugen-cgen-returns-to-loss-in-q1-2026-and-tests-bullish-p", "source_name": "Simply Wall Street", "published_at": "2026-05-19T22:40:05", "published_display": "19 May 2026 22:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Compugen Reports First Quarter 2026 Results", "summary": "Compugen has announced its first quarter 2026 financial results. This press release provides an overview of the company's performance during this period, likely including key financial metrics and operational highlights.", "url": "https://www.moomoo.com/news/post/70178547/press-release-compugen-reports-first-quarter-2026-results", "source_name": "Moomoo", "published_at": "2026-05-19T21:40:25", "published_display": "19 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Call Summary | Compugen(CGEN.US) Q1 2026 Earnings Conference", "summary": "This document is an earnings call summary for Compugen (CGEN.US) for their first quarter of 2026. However, no content is provided in the document itself to extract further details about the earnings.", "url": "https://www.moomoo.com/news/post/70192883/earnings-call-summary-compugen-cgenus-q1-2026-earnings-conference", "source_name": "Moomoo", "published_at": "2026-05-19T20:08:59", "published_display": "19 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEN: AI-driven immuno-oncology pipeline advances, with strong partnerships and extended cash runway", "summary": "Compugen Ltd. (CGEN) is making progress in its AI-driven immuno-oncology pipeline, notably with COM701 for ovarian cancer, and has secured key collaborations with Gilead and AstraZeneca. The company's financial stability, supported by royalty monetization, enables continued inves", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3348173:0-cgen-ai-driven-immuno-oncology-pipeline-advances-with-strong-partnerships-and-extended-cash-runway/", "source_name": "TradingView", "published_at": "2026-05-19T15:02:21", "published_display": "19 May 2026 15:02", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program (NASDAQ:CGEN)", "summary": "Compugen (CGEN) maintains a \"Buy\" rating due to advancing clinical programs and upcoming oncology catalysts. Its drug Rilvegostomig, partnered with AstraZeneca, shows promising phase 1b/2 data with a 70% cORR in HER2+ gastric cancer and will have new data presented at ASCO 2026. ", "url": "https://seekingalpha.com/article/4906399-compugen-buy-as-early-gastric-cancer-data-reinforces-rilvegostomig-program", "source_name": "Seeking Alpha", "published_at": "2026-05-19T12:39:21", "published_display": "19 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Reports Q1 Revenue and Long-Term Financial Stabi", "summary": "Compugen Ltd (CGEN) reported Q1 revenue of $2.2 million and projected its cash reserves to support operations through 2029, maintaining a debt-free status. Despite a low P/E ratio of 7.47x suggesting it might be undervalued, its GF Score\u2122 of 60 reflects moderate investment qualit", "url": "https://www.gurufocus.com/news/8866012/compugen-cgen-reports-q1-revenue-and-longterm-financial-stability?mobile=true%3Fmobile%3Dtrue&mobile=true%3Fmobile%3Dtrue%3Fmobile%3Dtrue&mobile=true&mobile=true", "source_name": "GuruFocus", "published_at": "2026-05-18T22:10:28", "published_display": "18 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd. (NASDAQ: CGEN) files $400M shelf; $100M ATM with Leerink", "summary": "Compugen Ltd. (NASDAQ: CGEN) has filed a shelf registration statement (Form F-3) to offer up to $400 million in various securities, including ordinary shares, debt securities, rights, warrants, and units. This includes a $100 million \"at-the-market\" (ATM) sales agreement with Lee", "url": "https://www.stocktitan.net/sec-filings/CGEN/f-3-compugen-ltd-foreign-issuer-shelf-registration-9df6127a1be6.html", "source_name": "Stock Titan", "published_at": "2026-05-18T21:10:28", "published_display": "18 May 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/fa4dd678-d685-3c17-9832-657d81021227/compugen-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-18T14:08:24+00:00", "published_display": "18 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/compugen-q1-earnings-snapshot-115816067.html", "source_name": "Associated Press", "published_at": "2026-05-18T11:58:16+00:00", "published_display": "18 May 2026 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Compugen\u2019s Q1 2026 revenue beats forecast, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQZzJyNExLeXR6angxV1p4VnVnWjdzWDBldzByVmQ5NzhBSm5fZmo0aUo1NmdLSDRJRG1sVnFvQXBxVER0LVh0NXgyWXluSlRGRUlFTjJuQzZwWDlfQURESGhETjc2aHRscFdTQ09TN0tXZHdLT1ZRYXZza01QaVNNRjFmeEwydU9jZDRFajdfZlV0b0RYQXZWWmI3U05pNW9HUG93OE9aRE9TRm5WNm5wV0tkLXF1RXdzSU5qbVBodktRWEoyUmZkcm5hOHpsUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPUGEN ($CGEN) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNTm1aME9EM0ZZMWFITWdObFNOUF8weTNMQmFOUDRvRFVBaEcxdEhBM0xsZ3BXSmg5WWxPYXpha1JtNUtybl9uMXpRYjNLUlloREZpNFdfcWhUMW9HSjJ0MkY0NWkyR1pTc0hxMlp2dVhQMThYRFFzaktvSzFOUmRiRVhSeHQtbE5L?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOMEd1eDNwUERIZ0cwWE9hRUVWN2c2R1BRU0RkT29yeU9PT05BSTZ1dXp1X0E4aHpsZVNSV1lwYi00RFZCVG1yZ0NxVlRZMVRaRU9PTHM4RTJKWTRhY0lBQlNuSEgyaVQ0VFgwelFnbGR1UTREUjFjaUJDaUduVnp5YWJrVXdsbVpZOXdKX1VrYWxrVGl1djZTR1BB?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNY0xpdjJFOHJ6T2ZCWmI3YW9KM2Jzb0ItYnd2clcxWHEtcEpvTXZ6ZEctd0xxZzd1SUNQOGl2aTFTNElNai10bFBXNmEzbkRzRUQ4cjFGczN6dzVvejVid3NQMVRDcklyOHhUNEpBbTZaZjc3WkowYy1idlFaQVBmNC00OC1DbmcycTQyZkRJOVFnLVBMcV9tcDh5NE9WWE9neG9KbTVxU3lxY2M?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cancer immunotherapy firm Compugen joins Stifel oncology forum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOaXFtVlB0LW90RHNfQzdLR3E0eDRTRUh6bWtXRkFzdXJsdmZFNjRKQnk4RFNnSVhVOTBxcWRvY0xlUXhieUJMdF9RTHBZQUxyczRjeGl3QThOc0wzLVJfWnFaNDF6dDhYeWhOSDVXRWFYUTY2bUJld2xzUm8tR2tFeWxhZjFaYmoyNmFlUjNzRTdyZmVWX2lmVmxJbVdLZVZ0VEgxWF9EcXExR0lFSFl6Y2JhVlRKYkVkVXRz?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Compugen sets May 18 earnings release, 8:30 AM ET webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPcHlVMW1xdVc0SUpMMnFwNElIemJyZlRrMjBpaUlpZURmNlhlUWpzZ19rWEJhUzV3QVJsbmNDR2RHYzRzWHVSM2JrRHUxeU00TDFsVS01cTc5UlU0eUlSamlVRGg4cW9rRjljWlVna2VYRlpCTGdBVHRwX2swVXlOZXdtQ3dGakc3X2FGTWFmYnJpaWN2Y1RrNjFoenRWUlVadWRJbzRUUVdxQ1RRR3kzbUdSX0E0S25Hd1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the outlook for Compugen (CGEN) stock today (Climbs Higher) 2026-04-27 - Bollinger Expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNR2xUNW9yazhrdTktQjJJTWtNZEdvVmN4WlVEX1RfZjl4bzRvNl9tV1FUaVBMMEZvME5UdGpqWDZFeTBTdUgzNmNpeVpDekZ2UmhEbDZJSE9wNW1vcWlzdGlmdi1UMUl6aFdRQ1dYWk50R081ekJGdFhEV3pBODdSWWxnSDRYU2p1czR6QUFrVHpoNWJfQ1hJR2tmTjYwTVFzV0MzSy0yZUJBOHVod0o2ellsNA?oc=5", "source_name": "newsline.com", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate sells and proposes sales at CGEN (NASDAQ: CGEN) \u2014 4,000 shares planned", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPMnZCb1BpeXd2WEw3NWt5aVc2RllLTEVFWkpkV0hDZGlSVkUtOU9sZl8wUEhJcVVXcVNTVW5DbXo5N19FLTJWNkxrVkF3bW5IOHdFLTl6MGlyekllMHFVZW03YWNLaHJOWl9jbGk1X2liMURNa0NDMzFxLUcxRTJJeUo4Yng1N1lmZFlDa0tzOHB4ZWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ophir Eran plans resale of 5,000 shares (Nasdaq: CGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxORy04NU91Q29mTkxwOFBIbXVrNzN2dHhSYUE1aDQyTWZSMmxGYzJ3ZzBDU09VSENoVUVZcTlSUWttQjkyeW9ia3pBUGxZc2tSTXR5Qk9fNUg0bVdEWndXMVNhMDdWSFRNd29JRkZ3WGFUOEJ5MHF5dzVRMXcwb0pmWVRTemZ0bDVpeTRQR3NleWVyYms?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Compugen management takes virtual Needham healthcare stage April 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOb0FfSXRMc2gxV2xxSVZfbFdqa3NQWmJnYVlEZWxFRG14a1hOUW83VmNpTVhfYlJmeUFHVnVLNmlxZjRlektyTFdobDhTWUtiMHo4Q3FSaFBkYWF3eEZ4Y0VEUWEzRXNIOWs1SWdkTlNvRHJrV1ZzV3dKODJxUXJ4WHY3N3BXTFNBRjhRZ3FLYTBvLS0xbjRTeTRGemFjbzNUSUlEUGNaZjZYcXVjVWctNWE2dGFqVTEyWnhHcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Initiates Coverage with 'Buy' Rating by Lake Str", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOelZyU3R5eXdkNXVYTV9kWVU0LU1HbEVRbDNsMkRoZXlaUmR5ZU9pck5uSTVFMTFKQ3lQMmMxcnZJRDl6SW10TGpVY1hIeXhXWktTRExfRnVzTlRjazJGMl9LTnZGX3RJRFhXeDNxbGRRMklRSEpxY1V1NVUzMUFPWjc3Qm9RcmFMa2NnVWZ2M2FRbml0dk1KX0d0eFVURVpGWjN6XzdIODgybWtVcnZNUk5ydndTZ0ZJVEZvS1Fha0FxWWJEUXhyVEdR?oc=5", "source_name": "GuruFocus", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE1Ob29ZYXVXU3B2NkxPSURLM0RXblJCazRhNWZtZjI4X3Y3REk2QktSMjdXVlRpdm4tb3ZzMDVEMEtLdUNfdlM1MmxtS1BITHFJMHlodFFLUndIaFZ5WU8zTTJEVGdPY0dJYmh6VW5KdWdvSXVET1hPTGJVMlJzWG8?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQTktNNTlrRWwxeWZfLWJadUMtVGZFWUYwblhueUlwcTRCQjFoMllaME9QUkVtcEFERVljTWEySl95TmQxWHNrMmlVcWpkR2N2enJ0UDRWb2FrTXdjTTN0QXVrSjloZUxnM2RfS0FDcFlDemlSRXJ4c0w5Y2dqcEJQV0pzaw?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca deal extends Compugen cash runway to 2029 after $65M payment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcmtfR2tnb283RmxIWmxWbTRINGdDTFgxOGJHU3VZcFV6U2F1ZGtDb1dVV2swa3VhT1BGdFlwU2FZRy15YWVKcUlEdF90ODNDZVJ3emtocjhNUEx2dmpDYy0taU5XYlZCTkl4WGJpaW42NndaTjNTb1hiYXoxOW53OEgyZjRQNTZfcjFPdVdaMDlSVXBWZmxrUkswVXkwMlAwVDJRWTdIVUo?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPUGEN ($CGEN) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZnV5MXpFcHdWOEJqZkttbERWUl9ibTV1dTRUYnJrdUtqSjJtT1M1a1pHam8wVC1ESjVQekJBMW5hc3h6alJwN29kWWJDUVN3YjJGMU9kV0FfdXl3dXhDellnM1hjUDlpYU80N1pRYUhYUGdENGFXV2pSQ2pQODVicGxqR1A3TzVj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNeEtmMFI0aDZ3MS1STFpyZzVtZzlHWEhacF9IdEE4ZVZOOXlnbHBLSWV3WjVzRnA1MjVWQjFzRERIY29QaGdlVlVaOXBvT1lmbWlIZnd2d19qVXdmeGcwZlplWDJ4REZ2S3hUX0VfaVBsNlBQOW9KOUJteTZLbFljRC1VZmdDN2pUWExlanUyRjhuVEwtQ3AwWV84dDdHUXB1bVFvLXU1ZDJxMU5PTG9QMk9KWDNtdEZhSEM2aTI3Z2RiY2FJYWJZM0l2bHhHazRQcnJMX1hvVGFKUWQ4bi1qTGxNVHZZd1nSAewBQVVfeXFMTm1HOFFxSGR3TUhXTDAtQjFvN2VPMkI4dU1JWXYxMDVNYm5kX1ZLSFpwWmdWbl9aaW5FdEhZNnNYbmFNM1pXTVRxVUI0cFlhcmp0ME1MRFRxV2FadGtXZ0tSX0ZfTjZ0dEdYMEptU3hJUmtycEJ3TTdGV3NjRDllcmZBLXNUX2p2MDVEY21wQXExdkNUVWxrc0c4Rkg5NVlhY0hhWmVmQ0VhWFJDS2NGbE9GT0IyYUZRckRJblRMTkxoN1RkaDBTaVN6T2tNbC1IQUlubHc4bjkzekNMWGNtZjRpd3hQSDFTYlRUZUk?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Compugen Stock: Runway Into 2027 But Expensive (NASDAQ:CGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPY244MTJ4cXJmU0RPNWtKMTZIbHgtZkktTzZ4bW9lNVgwQlNvWTFsTWZRdmFaTDNMejR2YzFURWhRZVVKeUFoMG1CQkhXOHdGZnozVlBzUWo3WUhXcnk0UFpNRUtqTE9ZR29zci1JNGZJNlpzT0pjZGhHSEVlbTlzVTNmaDBMOHpsZ2pUbjlLSQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-07T07:00:00+00:00", "published_display": "07 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-02T07:00:00+00:00", "published_display": "02 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes Compugen Ltd's (CGEN) valuation, noting its current valuation score is 7.48, placing it 228th out of 389 in the Biotechnology & Medical Research industry. CGEN's P/E ratio stands at 5.36, significantly below its recent high and above its recent low. However,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T05:09:59", "published_display": "19 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Compugen Ltd (CGEN), detailing its price momentum score of 6.72 and its ranking in the Biotechnology & Medical Research industry. It highlights the stock's current trading range between support at $1.67 and resistance at $2.64, suitab", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/technical", "source_name": "TradingKey", "published_at": "2026-06-18T17:40:40", "published_display": "18 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen presents ovarian cancer trial poster at ESMO meeting", "summary": "Compugen Ltd. presented a trial-in-progress poster for its MAIA-ovarian adaptive platform trial of COM701 at the ESMO Gynaecological Cancers Congress. The company is evaluating COM701 as a maintenance treatment for relapsed platinum-sensitive ovarian cancer, with initial data exp", "url": "https://m.uk.investing.com/news/stock-market-news/compugen-presents-ovarian-cancer-trial-poster-at-esmo-meeting-93CH-4735079?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T17:09:04", "published_display": "18 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/compugen-presents-trial-progress-poster-110000732.html", "source_name": "PR Newswire", "published_at": "2026-06-18T11:00:00+00:00", "published_display": "18 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen spotlights COM701 ovarian trial at ESMO congress", "summary": "Compugen (Nasdaq: CGEN) presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress 2026 for its MAIA-ovarian adaptive platform trial of COM701. COM701 is a potential first-in-class anti-PVRIG antibody being evaluated as a maintenance treatment for relapsed p", "url": "https://www.stocktitan.net/news/CGEN/compugen-presents-a-trial-in-progress-poster-on-the-maia-ovarian-1ujs4cnexnts.html", "source_name": "Stock Titan", "published_at": "2026-06-18T10:39:17", "published_display": "18 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Institutional Confidence", "summary": "Compugen Ltd (CGEN) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding stands at 14.54%, a 16.20% decrease quarter-over-quarter. James Simons is the largest instituti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:17", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Compugen Ltd (CGEN), noting its financial score of 6.25 and ranking in the Biotechnology & Medical Research industry. It highlights the company's robust financial status despite low operating efficiency, with recent quarterly revenue ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:25", "published_display": "18 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions", "summary": "Compugen (CGEN) is experiencing mixed analyst sentiment, with one firm significantly lowering its price target from US$13 to US$5, while another maintains a fair value estimate at US$4.6. Despite some bullish takes and continued \"Outperform\" ratings, more cautious voices cite tig", "url": "https://uk.finance.yahoo.com/news/compugen-cgen-stock-faces-mixed-043936924.html", "source_name": "Market source", "published_at": "2026-06-18T04:39:17", "published_display": "18 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBJU0R2M0VwQWdybFdtWEtJdTV2NFVnRWoyU0FCYUNfbHF1d19lblZBZUZ3ZFhXTF91SVpzLXdOLWttZ3JUVWV6clZSUGtDSGxaM3dwQ29sYmN3ZUs4bS1tUnMxYkprMGpZcDk1a0Vn?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T20:57:48+00:00", "published_display": "17 Jun 2026 20:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Compugen Ltd (CGEN) has an earnings forecast score of 9.20, ranking 8th in its industry, with analysts assigning a Strong Buy rating and an average price target of $4.00. The company's EPS for the previous quarter was $0.60, significantly exceeding market expectations, and the ne", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:17", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE4tdUp5dnlpZTVmUjRLWFk1aWRoNE5vWmJQQ0ZaTS1RUEpzLU9PNFpNeEhycWVXNEdSd25wcXRYT0g4NUd0N0QzTC1GQUtxM2gtdXRmcGpRZFhoREZUSUg1aVIwV1R0TUtnQnJkX0liVGI3ZHd6Rmlj?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T20:25:31+00:00", "published_display": "17 Jun 2026 20:25", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Compugen Ltd (CGEN) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also presents current stock price inform", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cgen/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:17", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026", "summary": "Compugen Ltd. announced it will present a poster on its MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The poster will detail the adaptive platform clinical trial evaluating the safety and efficacy of COM701 maintenance treatment in relapse", "url": "https://finance.yahoo.com/sectors/healthcare/articles/compugen-present-phase-1-maia-110000380.html", "source_name": "Market source", "published_at": "2026-06-12T02:10:11", "published_display": "12 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) to Present MAIA-Ovarian Trial Progress at Eu", "summary": "Compugen Ltd (CGEN) announced it will present progress on its MAIA-ovarian trial at the ESMO Gynecological Cancers Congress in June 2026. GuruFocus rates CGEN as 61.0% undervalued with a GF Value of $5.12, but flags it as a \"Possible Value Trap\" due to mixed profitability and gro", "url": "https://www.gurufocus.com/news/8912266/compugen-ltd-cgen-to-present-maiaovarian-trial-progress-at-european-oncology-congress?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-11T18:40:26", "published_display": "11 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen to present ovarian cancer trial poster at ESMO", "summary": "Compugen Ltd. announced it will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study at the ESMO Gynaecological Cancers Congress 2026. The study evaluates COM701 as a maintenance treatment for relapsed platinum-sensitive ovarian cancer. This news follows Compugen'", "url": "https://m.uk.investing.com/news/stock-market-news/compugen-to-present-ovarian-cancer-trial-poster-at-esmo-93CH-4723510?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-11T15:09:28", "published_display": "11 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI-driven cancer firm to present ovarian trial at ESMO 2026", "summary": "Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The presentation will cover COM701 maintenance treatment in relapsed plati", "url": "https://www.stocktitan.net/news/CGEN/compugen-to-present-phase-1-maia-ovarian-trial-in-progress-poster-at-59j5ab82cr00.html", "source_name": "Stock Titan", "published_at": "2026-06-11T10:39:43", "published_display": "11 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development", "summary": "Compugen Ltd. (Nasdaq: CGEN) announced its participation in Jones Trading's \"Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ML-based Drug Development\" on Monday, June 15, 2026. The company, a clinical-stage cancer immunotherapy firm leveraging it", "url": "https://www.tradingview.com/news/prnewswire:1bdb72de337c1:0-compugen-to-participate-in-jones-trading-fireside-chat-series-with-leaders-in-ai-ml-based-drug-development/", "source_name": "TradingView", "published_at": "2026-06-08T11:10:35", "published_display": "08 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] COMPUGEN LTD SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOdkFZVEpYaWhQVDBYc2lJNWlnQVhuOXRZem9OUDRuU1d2MVdrcVY4NzJ2T1lOVUljZVluZWdVWVc2a1lHMVJyanpRWFRKLTVRTnJya1h6dWdzcnJVdFR6VUwyUC1uazVOTDlUOVJHNnNSUjBZSWQ2YUJnLVM3Njlod3Fhd0dYRl9FR3FoS0RaVXc0YkRrSHg4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Compugen stock rating on ASCO data", "summary": "H.C. Wainwright has reiterated its Buy rating and $4.00 price target for Compugen shares (NASDAQ:CGEN) following positive updates on rilvegostomig presented at ASCO, a drug developed in partnership with AstraZeneca. Despite strong clinical data that validates the TIGIT mechanism ", "url": "https://m.uk.investing.com/news/stock-market-news/hc-wainwright-reiterates-compugen-stock-rating-on-asco-data-93CH-4713691?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-04T13:09:22", "published_display": "04 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Compugen stock rating on ASCO data By Investing.com", "summary": "H.C. Wainwright reiterated a Buy rating and a $4.00 price target for Compugen (NASDAQ: CGEN) following updates on rilvegostomig data presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting. AstraZeneca, Compugen's partner, provided positive updates on th", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-compugen-stock-rating-on-asco-data-93CH-4675770", "source_name": "Investing.com Canada", "published_at": "2026-06-04T11:42:17", "published_display": "04 Jun 2026 11:42", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOS1lOWVhKRGJBSERJeTktbmpUbWMzNFc4NlBhN0g5ajFjdjhSNlRsekVuczBDQXRBVlJ6dkdwUFZUWWU1NWswWTFpSTh3cHNod3pYV2FCNjN5VFBtNGhXSkRqenlZTmNSOEcyc2dtTFFOYTZFbzNBdVhWSURvd3hmYWN3N3FQM1VacTFEZl83UldiVFNMSUl2T2szWXRFRFBweUN5dEpn?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Q1 2026 Earnings Call: Complete Transcript", "summary": "Compugen discussed its Q1 2026 financial results, highlighting a strong cash runway extending into 2029 following a $65 million transaction with AstraZeneca. The company is actively enrolling patients for its COM701 clinical program for ovarian cancer, with interim data expected ", "url": "https://www.sahmcapital.com/news/content/compugen-q1-2026-earnings-call-complete-transcript-2026-06-01", "source_name": "Sahm", "published_at": "2026-06-01T11:09:22", "published_display": "01 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Compugen to Report Financial Results Pre-market on May 18", "summary": "Compugen Ltd. (NASDAQ: CGEN) is scheduled to release its financial results for the first quarter of 2026 before the market opens on Saturday, May 18, 2026. The company will also host a conference call and live webcast to discuss the results and provide a corporate update. Investo", "url": "https://www.moomoo.com/news/post/69868944/earnings-preview-compugen-to-report-financial-results-pre-market-on", "source_name": "Moomoo", "published_at": "2026-05-27T23:09:43", "published_display": "27 May 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges", "summary": "Compugen Ltd (CGEN) reported Q1 2026 results highlighting strategic advances in its COM701 clinical program for ovarian cancer and a solid cash runway into 2029. Despite a slight revenue dip and increased R&D expenses leading to a higher net loss, the company emphasized promising", "url": "https://ca.investing.com/news/company-news/compugen-ltd-cgen-q1-2026-earnings-call-highlights-strategic-advances-amid-financial-challenges-4658310", "source_name": "Investing.com Canada", "published_at": "2026-05-26T03:10:36", "published_display": "26 May 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5", "summary": "Leerink Partners has reiterated its Buy rating for Compugen (CGEN.US) but has revised its price target downward to $5. This adjustment reflects an updated outlook from the analytical firm while still signaling confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/70380757/leerink-partners-maintains-compugen-cgenus-with-buy-rating-cuts-target", "source_name": "Moomoo", "published_at": "2026-05-22T18:09:39", "published_display": "22 May 2026 18:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEN Maintains Outperform Rating -- Price Target Lowered to $5.0", "summary": "Leerink Partners has maintained an \"Outperform\" rating for Compugen (CGEN) but significantly lowered its price target from $13.00 to $5.00, reflecting a reassessment of its market position despite ongoing clinical-stage programs. Although the stock is considered undervalued by Gu", "url": "https://www.gurufocus.com/news/8875120/cgen-maintains-outperform-rating-price-target-lowered-to-500-by-leerink-partners", "source_name": "GuruFocus", "published_at": "2026-05-21T16:39:42", "published_display": "21 May 2026 16:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Returns To Loss In Q1 2026 And Tests Bullish Profitability Narrative", "summary": "Compugen (CGEN) reported a loss of US$7.7 million in Q1 2026 with revenue of US$2.2 million, challenging its recent profitability narrative. The majority of its trailing twelve-month revenue was driven by a single large payment in Q4 2025, raising questions about revenue stabilit", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgen/compugen/news/compugen-cgen-returns-to-loss-in-q1-2026-and-tests-bullish-p", "source_name": "Simply Wall Street", "published_at": "2026-05-19T22:40:05", "published_display": "19 May 2026 22:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Compugen Reports First Quarter 2026 Results", "summary": "Compugen has announced its first quarter 2026 financial results. This press release provides an overview of the company's performance during this period, likely including key financial metrics and operational highlights.", "url": "https://www.moomoo.com/news/post/70178547/press-release-compugen-reports-first-quarter-2026-results", "source_name": "Moomoo", "published_at": "2026-05-19T21:40:25", "published_display": "19 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Call Summary | Compugen(CGEN.US) Q1 2026 Earnings Conference", "summary": "This document is an earnings call summary for Compugen (CGEN.US) for their first quarter of 2026. However, no content is provided in the document itself to extract further details about the earnings.", "url": "https://www.moomoo.com/news/post/70192883/earnings-call-summary-compugen-cgenus-q1-2026-earnings-conference", "source_name": "Moomoo", "published_at": "2026-05-19T20:08:59", "published_display": "19 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CGEN: AI-driven immuno-oncology pipeline advances, with strong partnerships and extended cash runway", "summary": "Compugen Ltd. (CGEN) is making progress in its AI-driven immuno-oncology pipeline, notably with COM701 for ovarian cancer, and has secured key collaborations with Gilead and AstraZeneca. The company's financial stability, supported by royalty monetization, enables continued inves", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3348173:0-cgen-ai-driven-immuno-oncology-pipeline-advances-with-strong-partnerships-and-extended-cash-runway/", "source_name": "TradingView", "published_at": "2026-05-19T15:02:21", "published_display": "19 May 2026 15:02", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program (NASDAQ:CGEN)", "summary": "Compugen (CGEN) maintains a \"Buy\" rating due to advancing clinical programs and upcoming oncology catalysts. Its drug Rilvegostomig, partnered with AstraZeneca, shows promising phase 1b/2 data with a 70% cORR in HER2+ gastric cancer and will have new data presented at ASCO 2026. ", "url": "https://seekingalpha.com/article/4906399-compugen-buy-as-early-gastric-cancer-data-reinforces-rilvegostomig-program", "source_name": "Seeking Alpha", "published_at": "2026-05-19T12:39:21", "published_display": "19 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Reports Q1 Revenue and Long-Term Financial Stabi", "summary": "Compugen Ltd (CGEN) reported Q1 revenue of $2.2 million and projected its cash reserves to support operations through 2029, maintaining a debt-free status. Despite a low P/E ratio of 7.47x suggesting it might be undervalued, its GF Score\u2122 of 60 reflects moderate investment qualit", "url": "https://www.gurufocus.com/news/8866012/compugen-cgen-reports-q1-revenue-and-longterm-financial-stability?mobile=true%3Fmobile%3Dtrue&mobile=true%3Fmobile%3Dtrue%3Fmobile%3Dtrue&mobile=true&mobile=true", "source_name": "GuruFocus", "published_at": "2026-05-18T22:10:28", "published_display": "18 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd. (NASDAQ: CGEN) files $400M shelf; $100M ATM with Leerink", "summary": "Compugen Ltd. (NASDAQ: CGEN) has filed a shelf registration statement (Form F-3) to offer up to $400 million in various securities, including ordinary shares, debt securities, rights, warrants, and units. This includes a $100 million \"at-the-market\" (ATM) sales agreement with Lee", "url": "https://www.stocktitan.net/sec-filings/CGEN/f-3-compugen-ltd-foreign-issuer-shelf-registration-9df6127a1be6.html", "source_name": "Stock Titan", "published_at": "2026-05-18T21:10:28", "published_display": "18 May 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/fa4dd678-d685-3c17-9832-657d81021227/compugen-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-18T14:08:24+00:00", "published_display": "18 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/compugen-q1-earnings-snapshot-115816067.html", "source_name": "Associated Press", "published_at": "2026-05-18T11:58:16+00:00", "published_display": "18 May 2026 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Compugen\u2019s Q1 2026 revenue beats forecast, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQZzJyNExLeXR6angxV1p4VnVnWjdzWDBldzByVmQ5NzhBSm5fZmo0aUo1NmdLSDRJRG1sVnFvQXBxVER0LVh0NXgyWXluSlRGRUlFTjJuQzZwWDlfQURESGhETjc2aHRscFdTQ09TN0tXZHdLT1ZRYXZza01QaVNNRjFmeEwydU9jZDRFajdfZlV0b0RYQXZWWmI3U05pNW9HUG93OE9aRE9TRm5WNm5wV0tkLXF1RXdzSU5qbVBodktRWEoyUmZkcm5hOHpsUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPUGEN ($CGEN) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNTm1aME9EM0ZZMWFITWdObFNOUF8weTNMQmFOUDRvRFVBaEcxdEhBM0xsZ3BXSmg5WWxPYXpha1JtNUtybl9uMXpRYjNLUlloREZpNFdfcWhUMW9HSjJ0MkY0NWkyR1pTc0hxMlp2dVhQMThYRFFzaktvSzFOUmRiRVhSeHQtbE5L?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOMEd1eDNwUERIZ0cwWE9hRUVWN2c2R1BRU0RkT29yeU9PT05BSTZ1dXp1X0E4aHpsZVNSV1lwYi00RFZCVG1yZ0NxVlRZMVRaRU9PTHM4RTJKWTRhY0lBQlNuSEgyaVQ0VFgwelFnbGR1UTREUjFjaUJDaUduVnp5YWJrVXdsbVpZOXdKX1VrYWxrVGl1djZTR1BB?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNY0xpdjJFOHJ6T2ZCWmI3YW9KM2Jzb0ItYnd2clcxWHEtcEpvTXZ6ZEctd0xxZzd1SUNQOGl2aTFTNElNai10bFBXNmEzbkRzRUQ4cjFGczN6dzVvejVid3NQMVRDcklyOHhUNEpBbTZaZjc3WkowYy1idlFaQVBmNC00OC1DbmcycTQyZkRJOVFnLVBMcV9tcDh5NE9WWE9neG9KbTVxU3lxY2M?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer immunotherapy firm Compugen joins Stifel oncology forum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOaXFtVlB0LW90RHNfQzdLR3E0eDRTRUh6bWtXRkFzdXJsdmZFNjRKQnk4RFNnSVhVOTBxcWRvY0xlUXhieUJMdF9RTHBZQUxyczRjeGl3QThOc0wzLVJfWnFaNDF6dDhYeWhOSDVXRWFYUTY2bUJld2xzUm8tR2tFeWxhZjFaYmoyNmFlUjNzRTdyZmVWX2lmVmxJbVdLZVZ0VEgxWF9EcXExR0lFSFl6Y2JhVlRKYkVkVXRz?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen sets May 18 earnings release, 8:30 AM ET webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPcHlVMW1xdVc0SUpMMnFwNElIemJyZlRrMjBpaUlpZURmNlhlUWpzZ19rWEJhUzV3QVJsbmNDR2RHYzRzWHVSM2JrRHUxeU00TDFsVS01cTc5UlU0eUlSamlVRGg4cW9rRjljWlVna2VYRlpCTGdBVHRwX2swVXlOZXdtQ3dGakc3X2FGTWFmYnJpaWN2Y1RrNjFoenRWUlVadWRJbzRUUVdxQ1RRR3kzbUdSX0E0S25Hd1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the outlook for Compugen (CGEN) stock today (Climbs Higher) 2026-04-27 - Bollinger Expansion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNR2xUNW9yazhrdTktQjJJTWtNZEdvVmN4WlVEX1RfZjl4bzRvNl9tV1FUaVBMMEZvME5UdGpqWDZFeTBTdUgzNmNpeVpDekZ2UmhEbDZJSE9wNW1vcWlzdGlmdi1UMUl6aFdRQ1dYWk50R081ekJGdFhEV3pBODdSWWxnSDRYU2p1czR6QUFrVHpoNWJfQ1hJR2tmTjYwTVFzV0MzSy0yZUJBOHVod0o2ellsNA?oc=5", "source_name": "newsline.com", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate sells and proposes sales at CGEN (NASDAQ: CGEN) \u2014 4,000 shares planned", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPMnZCb1BpeXd2WEw3NWt5aVc2RllLTEVFWkpkV0hDZGlSVkUtOU9sZl8wUEhJcVVXcVNTVW5DbXo5N19FLTJWNkxrVkF3bW5IOHdFLTl6MGlyekllMHFVZW03YWNLaHJOWl9jbGk1X2liMURNa0NDMzFxLUcxRTJJeUo4Yng1N1lmZFlDa0tzOHB4ZWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ophir Eran plans resale of 5,000 shares (Nasdaq: CGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxORy04NU91Q29mTkxwOFBIbXVrNzN2dHhSYUE1aDQyTWZSMmxGYzJ3ZzBDU09VSENoVUVZcTlSUWttQjkyeW9ia3pBUGxZc2tSTXR5Qk9fNUg0bVdEWndXMVNhMDdWSFRNd29JRkZ3WGFUOEJ5MHF5dzVRMXcwb0pmWVRTemZ0bDVpeTRQR3NleWVyYms?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen management takes virtual Needham healthcare stage April 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOb0FfSXRMc2gxV2xxSVZfbFdqa3NQWmJnYVlEZWxFRG14a1hOUW83VmNpTVhfYlJmeUFHVnVLNmlxZjRlektyTFdobDhTWUtiMHo4Q3FSaFBkYWF3eEZ4Y0VEUWEzRXNIOWs1SWdkTlNvRHJrV1ZzV3dKODJxUXJ4WHY3N3BXTFNBRjhRZ3FLYTBvLS0xbjRTeTRGemFjbzNUSUlEUGNaZjZYcXVjVWctNWE2dGFqVTEyWnhHcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Initiates Coverage with 'Buy' Rating by Lake Str", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOelZyU3R5eXdkNXVYTV9kWVU0LU1HbEVRbDNsMkRoZXlaUmR5ZU9pck5uSTVFMTFKQ3lQMmMxcnZJRDl6SW10TGpVY1hIeXhXWktTRExfRnVzTlRjazJGMl9LTnZGX3RJRFhXeDNxbGRRMklRSEpxY1V1NVUzMUFPWjc3Qm9RcmFMa2NnVWZ2M2FRbml0dk1KX0d0eFVURVpGWjN6XzdIODgybWtVcnZNUk5ydndTZ0ZJVEZvS1Fha0FxWWJEUXhyVEdR?oc=5", "source_name": "GuruFocus", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE1Ob29ZYXVXU3B2NkxPSURLM0RXblJCazRhNWZtZjI4X3Y3REk2QktSMjdXVlRpdm4tb3ZzMDVEMEtLdUNfdlM1MmxtS1BITHFJMHlodFFLUndIaFZ5WU8zTTJEVGdPY0dJYmh6VW5KdWdvSXVET1hPTGJVMlJzWG8?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQTktNNTlrRWwxeWZfLWJadUMtVGZFWUYwblhueUlwcTRCQjFoMllaME9QUkVtcEFERVljTWEySl95TmQxWHNrMmlVcWpkR2N2enJ0UDRWb2FrTXdjTTN0QXVrSjloZUxnM2RfS0FDcFlDemlSRXJ4c0w5Y2dqcEJQV0pzaw?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca deal extends Compugen cash runway to 2029 after $65M payment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcmtfR2tnb283RmxIWmxWbTRINGdDTFgxOGJHU3VZcFV6U2F1ZGtDb1dVV2swa3VhT1BGdFlwU2FZRy15YWVKcUlEdF90ODNDZVJ3emtocjhNUEx2dmpDYy0taU5XYlZCTkl4WGJpaW42NndaTjNTb1hiYXoxOW53OEgyZjRQNTZfcjFPdVdaMDlSVXBWZmxrUkswVXkwMlAwVDJRWTdIVUo?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMPUGEN ($CGEN) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZnV5MXpFcHdWOEJqZkttbERWUl9ibTV1dTRUYnJrdUtqSjJtT1M1a1pHam8wVC1ESjVQekJBMW5hc3h6alJwN29kWWJDUVN3YjJGMU9kV0FfdXl3dXhDellnM1hjUDlpYU80N1pRYUhYUGdENGFXV2pSQ2pQODVicGxqR1A3TzVj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compugen Stock: Runway Into 2027 But Expensive (NASDAQ:CGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPY244MTJ4cXJmU0RPNWtKMTZIbHgtZkktTzZ4bW9lNVgwQlNvWTFsTWZRdmFaTDNMejR2YzFURWhRZVVKeUFoMG1CQkhXOHdGZnozVlBzUWo3WUhXcnk0UFpNRUtqTE9ZR29zci1JNGZJNlpzT0pjZGhHSEVlbTlzVTNmaDBMOHpsZ2pUbjlLSQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-07T07:00:00+00:00", "published_display": "07 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-02T07:00:00+00:00", "published_display": "02 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 61, "sentiment_summary": {"positive": 19, "negative": 9, "neutral": 33, "score": 54, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 75, "events": [{"event": "earnings", "label": "Earnings", "weight": 14.24, "count": 27}, {"event": "general", "label": "Market update", "weight": 10.25, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 5.3, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 2.01, "latest_week": "2026-06-19", "one_week_move": -1.5, "four_week_move": -28.2, "twelve_week_move": -1.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.500617, "market_dynamics_buy_signal": false, "relative_strength": -10.848691, "fair_value_gap": 15.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.7362, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.5% over one week, -28.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 10}, {"label": "TradingKey", "count": 8}, {"label": "GuruFocus", "count": 4}, {"label": "Moomoo", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 27}, {"label": "Market update", "count": 18}, {"label": "Analyst action", "count": 9}, {"label": "Balance sheet", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.5% over one week, -28.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis"}], "updated_at": "2026-06-23T03:39:03.863326+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}